Oncology
Advanced Soft-Tissue Sarcoma
3
Pipeline Programs↗
5
Active Trials↗
2
Companies Involved↗
Advanced Soft-tissue Sarcoma is an early-stage landscape with 3 programs across 2 companies. The most active players are Merck & Co., Novartis.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical2
Phase 1
No programs
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
8
clinical trials
Unknown status3 · 38%
Recruiting3 · 38%
Active, not recruiting2 · 25%
Clinical Trials
Trial Activity
8 trials
Cirtuvivint in Selected Advanced Soft-Tissue Sarcomas
Recruiting·AAsociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas·Phase 2·NCT07032285·25 enrolled
Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc)
Recruiting·AAsociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas·Phase 2·NCT06114004·88 enrolled
Molecular Profiling of Advanced Soft-tissue Sarcomas
Active, not recruiting·IInstitut National de la Santé Et de la Recherche Médicale, France·Phase 3·NCT03784014·603 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)